{"commentary":{"count":54,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":28,"youtube":17,"podcast":8,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05241860\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"A-DREAM","nct_id":"NCT05241860","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=a-dream-nct05241860. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"A-DREAM","arms":[{"description":"Patients stop both hormonal medications (medication to decrease testosterone levels in the body and potent oral hormonal medication to block growth signals from male hormones in the cancer cells). Patients are then followed every 12 months for symptoms. Patients with an increase in PSA level to greater than or equal to 5 ng/ml, changes on imaging studies suggesting that their cancer is growing back, or symptoms that the doctor thinks is related to their cancer growing back, resume both hormonal treatments. Patients undergo CT scans, MRI scans and bone scans prior to registration and throughout study. Patients may optionally undergo biopsies and additional collection of blood on study.","label":"Treatment (discontinue hormonal medication, follow up)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2033-09-01","type":"ESTIMATED"},"conditions":["Castration-Sensitive Prostate Carcinoma","Stage IV Prostate Cancer AJCC v8"],"enrollment":{"count":79,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pharmacotherapy Discontinuation","type":"OTHER"},{"name":"Follow-Up","type":"OTHER"},{"name":"Questionnaire Administration","type":"OTHER"},{"name":"Quality-of-Life Assessment","type":"OTHER"}],"last_update":"2026-09-24","lead_sponsor":"Alliance for Clinical Trials in Oncology","official_title":"A Phase 2 Trial of ADT Interruption in Patients Responding Exceptionally to AR-Pathway Inhibitor in Metastatic Hormone-Sensitive Prostate Cancer (MHSPC): A-DREAM","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-09-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Treatment-free With Eugonadal Testosterone (>= 150 ng/dl)","timeFrame":"At 18 months"}],"references":[],"start_date":{"date":"2022-11-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)","url":"https://clinicaltrials.gov/study/NCT05241860"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/a-dream-nct05241860"}